PAHC

Phibro Animal HealthD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$49.00

+48.3% vs current

Most likely

Base case

50%

Probability

Target price

$39.00

+18.0% vs current

B-

Bear case

20%

Probability

Target price

$28.00

-15.3% vs current

AI sentiment snapshot

Latest data as of 2026-06-08

AI commentary

Primary-source evidence is constructive: the company beat on sales, adjusted EBITDA, and adjusted EPS, raised FY26 guidance, and expanded liquidity. The main overhang is the Brazil antimicrobial regulatory change, and the packet does not surface a clean post-print analyst revision chain or a verified market-reaction series, so this remains a positive but monitoring-style setup rather than a high-conviction rerate.

RankAlpha Sentiment Codex - 2026-06-08

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-06eventQ3 beat and FY26 guidance raise improved the near-term setupMedium impact

Phibro reported fiscal Q3 net sales of $383.5 million (+10%), adjusted EBITDA of $60.8 million (+11%), and adjusted diluted EPS of $0.76 (+19%), then lifted FY26 guidance to $1.46 billion-$1.50 billion of sales and $247 million-$255 million of adjusted EBITDA, which is the main positive rerating input [#SEC-8K-2026-05-06].

2026-05-06catalystBrazil antimicrobial regulatory change is the main near-term overhangMedium impact

Management flagged a new Brazilian framework that removes growth-promotion and performance indications for certain antimicrobials, including virginiamycin and bacitracin, with a 180-day transition period; therapeutic registrations are said to be in the final stages of review, but the transition still creates mix and margin uncertainty [#SEC-8K-2026-05-06].

2026-06-30catalystFY26 execution and new platform optionality must convert the beat into durable cash flowHigh impact

The company also highlighted a $125 million increase in its revolving credit facility and the launch of its Sustainable Solutions Platform, including VERRATAIN Verified Sustainability Solutions, but the longer-term case still depends on executing through the regulatory transition and sustaining animal-health momentum [#SEC-8K-2026-05-06].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-08 • Updated nightlySource: Internal modelMethodology